For which patients with advanced breast cancer is Afinitor (everolimus) indicated?

Afinitor (everolimus), combined with exemestane, is indicated for postmenopausal women with hormone receptor-positive, HER2/neu-negative advanced breast cancer without symptomatic visceral disease, after recurrence or progression following a non-steroidal aromatase inhibitor.